Low-Grade Serous Ovarian Cancer (LGSOC)
Clinical Trials
The FDA has not yet approved any treatment specifically for LGSOC. However, new treatments for LGSOC are being studied right now, so it’s important to stay up to date on the latest research developments.
Understanding clinical trials
You may have heard of clinical trials while researching LGSOC. Clinical trials are studies run by healthcare professionals (HCPs) that can determine if a new medicine or treatment works and is safe for people to use. All new medicines and medicine combinations must go through clinical trials before they can be approved by the US Food and Drug Administration (FDA).
Clinical trials study different aspects of medicines and how they interact with the body. HCPs will determine the safest dose, which side effects are caused by the treatment, and if the treatment is effective.
Clinical trials for LGSOC
There are clinical trials going on right now that could lead to breakthrough treatments for people with LGSOC.
Treatments that have been shown to work in other cancers, as well as new therapies, may lead the way for more options to treat LGSOC in the future. Groundbreaking new approaches that could lead to treating LGSOC in a completely different way are being tested as well.
Take part
By signing up for a clinical trial, you may have the chance to try one of these new medicines before they are approved by the FDA. Taking part in a clinical trial may be life-changing, so it’s important that you consider signing up for a clinical trial if you are eligible.
These studies are investigating treatments or outcomes that have not received approval from a health authority. There is no guarantee that the outcome of these studies will result in approval.
Find a clinical trial for LGSOC
Click on one of the links below and follow the instructions to find ovarian cancer clinical trials for LGSOC. You can share the information you find with your doctor to start a conversation about clinical trials.
Clinicaltrials.gov
ClinicalTrials.gov is an online database of clinical research studies and information about their results.
Clearity
Clearity provides science-backed information and individualized support to patients, families, and caregivers.
Ovarian Cancer Research Alliance
Search for “low grade” when using the OCRA (Ovarian Cancer Research Alliance) clinical trial finder.
Being your own advocate
Kat talks about the power of self-advocacy and living with LGSOC.
What’s next
Taking care of yourself
Get information on managing the unique challenges that come with an LGSOC diagnosis.
References
Banerjee SN, Ring KL, Nieuwenhuysen EV, et al. Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC). J Clin Oncol. 2023;41(suppl 16):5515. doi:10.1200/JCO.2023.41.16_suppl.5515
Grisham RN, Slomovitz BM, Andrews N, et al. The highs and lows of serous ovarian cancer. Int J Gynecol Cancer. 2023;33(9):1331-1344.
American Cancer Society. Clinical trials: what you need to know. Accessed July 9, 2024. https://www.cancer.org/cancer/managing-cancer/making-treatment-decisions/clinical-trials/what-you-need-to-know.html
ClinicalTrials.gov. Low-grade trial search results. Accessed September 10, 2024. https://www.clinicaltrials.gov/search?cond=Low Grade Serous Ovarian Cancer
Koselugo® [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.
Femara® [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals; 2014.
Taxol® [Prescribing Information]. Princeton, NJ: Bristol-Myers Squibb Company; 2011.
Doxil® [Prescribing Information]. Raritan, NJ: Ortho Biotech Products, LP; 2007.
Soltamox® [Prescribing Information]. Raleigh, NC: Mayne Pharma US Inc.; 2019.
Hycamtin® [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2019.
Mekinist® [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2024.
Kisqali® [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2023.
Paraplatin® [Prescribing Information]. Princeton, NJ: Bristol-Myers Squibb Company; 2010.
Memorial Sloan Kettering Cancer Center. A phase II study of VS-6766 alone or with defactinib in women with metastatic low-grade serous ovarian cancer that came back. Accessed July 18, 2024. https://www.mskcc.org/cancer-care/clinical-trials/21-050
Han C, Bellone S, Zammataro L, et al. Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment. Gynecol Oncol Rep. 2018;25:41-44.
